Remdesivir was one of the first medications approved for treatment of COVID-19. Clinical studies evaluated its effectiveness, but did not generate conclusive results. A new analysis of the study data shows that a specific group of patients benefits the most from the drug.
Brabus Launches ‘Deep Blue’ G-Wagon, Speedboat & Luxury Watch Line
Brabus is unifying its collaborations with Mercedes-AMG, Finland’s Axopar Boats, and Panerai luxury watches under one Deep Blue collection.Being that Brabus is...
